1. Home
  2. UPLD vs NCEL Comparison

UPLD vs NCEL Comparison

Compare UPLD & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Upland Software Inc.

UPLD

Upland Software Inc.

HOLD

Current Price

$5.05

Market Cap

17.3M

Sector

Technology

ML Signal

HOLD

NCEL

NewcelX Ltd. Ordinary Shares

N/A

Current Price

$3.50

Market Cap

17.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UPLD
NCEL
Founded
2010
2008
Country
United States
Switzerland
Employees
N/A
4
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.3M
17.2M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
UPLD
NCEL
Price
$5.05
$3.50
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$3.75
N/A
AVG Volume (30 Days)
235.6K
30.5K
Earning Date
05-01-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
63.38
N/A
EPS
N/A
N/A
Revenue
$74,767,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.95
N/A
52 Week Low
$0.50
$1.83
52 Week High
$6.65
$5.12

Technical Indicators

Market Signals
Indicator
UPLD
NCEL
Relative Strength Index (RSI) 84.67 54.99
Support Level $0.62 $2.95
Resistance Level N/A $3.62
Average True Range (ATR) 0.29 0.24
MACD 0.49 0.01
Stochastic Oscillator 69.03 100.00

Price Performance

Historical Comparison
UPLD
NCEL

About UPLD Upland Software Inc.

Upland Software Inc is a software company. It provides cloud-based software applications in three categories: Knowledge Management that provides solutions designed to help organizations capture, organize, and distribute information to employees and customers. Content Lifecycle and Workflow Automation offers solutions that support document management, compliance, and process efficiency across various industries. Digital Marketing solutions that provides tools for audience engagement, campaign management, and content distribution across digital channels. Geographically, the company has operations in the U.S., United Kingdom and Canada, of which United States derives maximum revenue.

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.

Share on Social Networks: